|
1
|
Cove DJ, Hope IA and Quatrano RS: Polarity
in biological systems. Development Genetics, Epigenetics and
Environmental Regulation. Russo VEA, Cove DJ, Edgar LG, Jaenish R
and Salamini F: Springer-Verlag; New York: pp. 507–524. 1999
|
|
2
|
Sebbagh M and Borg JP: Insight into planar
cell polarity. Exp Cell Res. 328:284–295. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lee M and Vasioukhin V: Cell polarity and
cancer - cell and tissue polarity as a non-canonical tumor
suppressor. J Cell Sci. 121:1141–1150. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Assemat E, Bazellieres E,
Pallesi-Pocachard E, Le Bivic A and Massey-Harroche D: Polarity
complex proteins. Biochim Biophys Acta. 1778:614–630. 2008.
View Article : Google Scholar
|
|
5
|
Khursheed M and Bashyam MD: Apico-basal
polarity complex and cancer. J Biosci. 39:145–155. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lin WH, Asmann YW and Anastasiadis PZ:
Expression of polarity genes in human cancer. Cancer Inform.
14(Suppl. 3): 15–28. 2015.PubMed/NCBI
|
|
7
|
Kemphues KJ, Priess JR, Morton DG and
Cheng NS: Identification of genes required for cytoplasmic
localization in early C. elegans embryos. Cell. 52:311–320. 1988.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tepass U, Theres C and Knust E: crumbs
encodes an EGF-like protein expressed on apical membranes of
Drosophila epithelial cells and required for organization of
epithelia. Cell. 61:787–799. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bilder D and Perrimon N: Localization of
apical epithelial determinants by the basolateral PDZ protein
Scribble. Nature. 403:676–680. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Royer C and Lu X: Epithelial cell
polarity: A major gatekeeper against cancer? Cell Death Differ.
18:1470–1477. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gandalovicová A, Vomastek T, Rosel D and
Brábek J: Cell polarity signaling in the plasticity of cancer cell
invasiveness. Oncotarget. 7:25022–25049. 2016.PubMed/NCBI
|
|
12
|
Lin D, Edwards AS, Fawcett JP, Mbamalu G,
Scott JD and Pawson T: A mammalian PAR-3-PAR-6 complex implicated
in Cdc42/Rac1 and aPKC signalling and cell polarity. Nat Cell Biol.
2:540–547. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Vinot S, Le T, Maro B and Louvet-Vallée S:
Two PAR6 proteins become asymmetrically localized during
establishment of polarity in mouse oocytes. Curr Biol. 14:520–525.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Louvet-Vallée S, Vinot S and Maro B:
Mitotic spindles and cleavage planes are oriented randomly in the
two-cell mouse embryo. Curr Biol. 15:464–469. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Vinot S, Le T, Ohno S, Pawson T, Maro B
and Louvet-Vallée S: Asymmetric distribution of PAR proteins in the
mouse embryo begins at the 8-cell stage during compaction. Dev
Biol. 282:307–319. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kohjima M, Noda Y, Takeya R, Saito N,
Takeuchi K and Sumimoto H: PAR3beta, a novel homologue of the cell
polarity protein PAR3, localizes to tight junctions. Biochem
Biophys Res Commun. 299:641–646. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Cline EG and Nelson WJ: Characterization
of mammalian Par 6 as a dual-location protein. Mol Cell Biol.
27:4431–4443. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Dormoy V, Tormanen K and Sütterlin C:
Par6y is at the mother centriole and controls centrosomal protein
composition through a Par6a-dependent pathway. J Cell Sci.
126:860–870. 2013. View Article : Google Scholar :
|
|
19
|
Ellenbroek SI, Iden S and Collard JG: Cell
polarity proteins and cancer. Semin Cancer Biol. 22:208–215. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Davies L and Welch HG: Increasing
incidence of thyroid cancer in the United States, 1973–2002. JAMA.
295:2164–2167. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Jemal A, Siegel R, Ward E, Hao Y, Xu J and
Thun MJ: Cancer statistics, 2009. CA Cancer J Clin. 59:225–249.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kinder BK: Well differentiated thyroid
cancer. Curr Opin Oncol. 15:71–77. 2003. View Article : Google Scholar
|
|
23
|
Pasieka JL: Anaplastic thyroid cancer.
Curr Opin Oncol. 15:78–83. 2003. View Article : Google Scholar
|
|
24
|
Nikiforov YE, Biddinger PW and Thompson
LDR: Diagnostic Pathology and Molecular Genetics of the Thyroid.
Lippincott Williams & Wilkins; Philadelphia: 2009
|
|
25
|
Cancer Genome Atlas Research Network:
Integrated genomic characterization of papillary thyroid carcinoma.
Cell. 159:676–690. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kimura ET, Nikiforova MN, Zhu Z, Knauf JA,
Nikiforov YE and Fagin JA: High prevalence of BRAF mutations in
thyroid cancer: Genetic evidence for constitutive activation of the
RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma.
Cancer Res. 63:1454–1457. 2003.PubMed/NCBI
|
|
27
|
Soares P, Trovisco V, Rocha AS, Lima J,
Castro P, Preto A, Máximo V, Botelho T, Seruca R and
Sobrinho-Simoes M: BRAF mutations and RET/PTC rearrangements are
alternative events in the etiopathogenesis of PTC. Oncogene.
22:4578–4580. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Elisei R, Ugolini C, Viola D, Lupi C,
Biagini A, Giannini R, Romei C, Miccoli P, Pinchera A and Basolo F:
BRAFV600E mutation and outcome of patients with
papillary thyroid carcinoma: A 15-year median follow-up study. J
Clin Endocrinol Metab. 93:3943–3949. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kerjaschki D, Krisch K, Sleyter UB, Umrath
W, Jakesz R, Depisch D, Kokoschka R and Horandner H: The structure
of tight junctions in human thyroid tumors. A systematic
freeze-fracture study Am J Pathol. 96:207–226. 1979.
|
|
30
|
Fluge Ø, Haugen DR, Lillehaug JR and
Varhaug JE: Difference in patterns of Met expression in papillary
thyroid carcinomas and nonneoplastic thyroid tissue. World J Surg.
25:623–631. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Bai Y, Kakudo K, Nakamura M, Ozaki T, Li
Y, Liu Z, Mori I, Miyauchi A and Zhou G: Loss of cellular
polarity/cohesiveness in the invasive front of papillary thyroid
carcinoma and periostin expression. Cancer Lett. 281:188–195. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hedinger C, Williams ED and Sobin LH: The
WHO histological classification of thyroid tumors: a commentary on
the second edition. Cancer. 63:908–911. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Barollo S, Pennelli G, Vianello F,
Watutantrige Fernando S, Negro I, Merante Boschin I, Pelizzo MR,
Rugge M, Mantero F, Nacamulli D, et al: BRAF in primary and
recurrent papillary thyroid cancers: The relationship with
131I and 2-[18F]fluoro-2- deoxy-D-glucose
uptake ability. Eur J Endocrinol. 163:659–663. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Chomczynski P and Sacchi N: Single-step
method of RNA isolation by acid guanidinium
thiocyanate-phenol-chloroform extraction. Anal Biochem.
162:156–159. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Vandesompele J, De Preter K, Pattyn F,
Poppe B, Van Roy N, De Paepe A and Speleman F: Accurate
normalization of real-time quantitative RT-PCR data by geometric
averaging of multiple internal control genes. Genome Biol.
3:Research0034. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ulisse S, Baldini E, Sorrenti S, Barollo
S, Prinzi N, Catania A, Nesca A, Gnessi L, Pelizzo MR, Mian C, et
al: In papillary thyroid carcinoma BRAFV600E is
associated with increased expression of the urokinase plasminogen
activator and its cognate receptor, but not with disease-free
interval. Clin Endocrinol (Oxf). 77:780–786. 2012. View Article : Google Scholar
|
|
37
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2−ΔΔCT method. Methods. 25:402–408. 2001. View Article : Google Scholar
|
|
38
|
Bradford MM: A rapid and sensitive method
for the quantitation of microgram quantities of protein utilizing
the principle of protein-dye binding. Anal Biochem. 72:248–254.
1976. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Garg M, Okamoto R, Nagata Y, Kanojia D,
Venkatesan S, Anand MT, Braunstein GD, Said JW, Doan NB, Ho Q, et
al: Establishment and characterization of novel human primary and
metastatic anaplastic thyroid cancer cell lines and their genomic
evolution over a year as a primagraft. J Clin Endocrinol Metab.
100:725–735. 2015. View Article : Google Scholar :
|
|
40
|
Zen K, Yasui K, Gen Y, Dohi O, Wakabayashi
N, Mitsufuji S, Itoh Y, Zen Y, Nakanuma Y, Taniwaki M, et al:
Defective expression of polarity protein PAR-3 gene (PARD3) in
esophageal squamous cell carcinoma. Oncogene. 28:2910–2918. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Jan YJ, Ko BS, Liu TA, Wu YM, Liang SM,
Chen SC, Wang J and Liou JY: Expression of partitioning defective 3
(Par-3) for predicting extrahepatic metastasis and survival with
hepatocellular carcinoma. Int J Mol Sci. 14:1684–1697. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Dugay F, Le Goff X, Rioux-Leclerq N,
Chesnel F, Jouan F, Henry C, Cabillic F, Verhoest G, Vigneau C,
Arlot-Bonnemains Y, et al: Overexpression of the polarity protein
PAR-3 in clear cell renal cell carcinoma is associated with poor
prognosis. Int J Cancer. 134:2051–2060. 2014. View Article : Google Scholar
|
|
43
|
Nolan ME, Aranda V, Lee S, Lakshmi B, Basu
S, Allred DC and Muthuswamy SK: The polarity protein Par6 induces
cell proliferation and is overexpressed in breast cancer. Cancer
Res. 68:8201–8209. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Cunliffe HE, Jiang Y, Fornace KM, Yang F
and Meltzer PS: PAR6B is required for tight junction formation and
activated PKCZ localization in breast cancer. Am J Cancer Res.
2:478–491. 2012.
|
|
45
|
Marques E, Englund JI, Tervonen TA,
Virkunen E, Laakso M, Myllynen M, Mäkelä A, Ahvenainen M, Lepikhova
T, Monni O, et al: Par6G suppresses cell proliferation and is
targeted by loss-of-function mutations in multiple cancers.
Oncogene. 35:1386–1398. 2016. View Article : Google Scholar :
|
|
46
|
Eder AM, Sui X, Rosen DG, Nolden LK, Cheng
KW, Lahad JP, Kango-Singh M, Lu KH, Warneke CL, Atkinson EN, et al:
Atypical PKCiota contributes to poor prognosis through loss of
apical-basal polarity and cyclin E overexpression in ovarian
cancer. Proc Natl Acad Sci USA. 102:12519–12524. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Regala RP, Weems C, Jamieson L, Khoor A,
Edell ES, Lohse CM and Fields AP: Atypical protein kinase C iota is
an oncogene in human non-small cell lung cancer. Cancer Res.
65:8905–8911. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Iden S, van Riel WE, Schäfer R, Song JY,
Hirose T, Ohno S and Collard JG: Tumor type-dependent function of
the par3 polarity protein in skin tumorigenesis. Cancer Cell.
22:389–403. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Yao S, Bee A, Brewer D, Dodson A, Beesley
C, Ke Y, Ambroisine L, Fisher G, Mpller H, Dickinson T, et al:
PRKC-Z expression promotes the aggressive phenotype of human
prostate cancer cells and is a novel target for therapeutic
intervention. Genes Cancer. 1:444–464. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Awadelkarim KD, Callens C, Rossé C, Susini
A, Vacher S, Rouleau E, Lidereau R and Bièche I: Quantification of
PKC family genes in sporadic breast cancer by qRT-PCR: Evidence
that PKCi/7 overexpression is an independent prognostic factor. Int
J Cancer. 131:2852–2862. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Ma L, Tao Y, Duran A, Llado V, Galvez A,
Barger JF, Castilla EA, Chen J, Yajima T, Porollo A, et al: Control
of nutrient stress- induced metabolic reprogramming by PKCZ in
tumorigenesis. Cell. 152:599–611. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Namdarian B, Wong E, Galea R, Pedersen J,
Chin X, Speirs R, Humbert PO, Costello AJ, Corcoran NM and Hovens
CM: Loss of APKC expression independently predicts tumor recurrence
in superficial bladder cancers. Urol Oncol. 31:649–655. 2013.
View Article : Google Scholar
|
|
53
|
Knauf JA, Sartor MA, Medvedovic M,
Lundsmith E, Ryder M, Salzano M, Nikiforov YE, Giordano TJ,
Ghossein RA and Fagin JA: Progression of BRAF-induced thyroid
cancer is associated with epithelial-mesenchymal transition
requiring concomitant MAP kinase and TGFp signaling. Oncogene.
30:3153–3162. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Riesco-Eizaguirre G, Rodriguez I, De la
Vieja A, Costamagna E, Carrasco N, Nistal M and Santisteban P: The
BRAFV600E oncogene induces transforming growth factor
beta secretion leading to sodium iodide symporter repression and
increased malignancy in thyroid cancer. Cancer Res. 69:8317–8325.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Ozdamar B, Bose R, Barrios-Rodiles M, Wang
HR, Zhang Y and Wrana JL: Regulation of the polarity protein Par6
by TGFbeta receptors controls epithelial cell plasticity. Science.
307:1603–1609. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Gunaratne A, Thai BL and Di Guglielmo GM:
Atypical protein kinase C phosphorylates Par6 and facilitates
transforming growth factor p-induced epithelial-to-mesenchymal
transition. Mol Cell Biol. 33:874–886. 2013. View Article : Google Scholar :
|
|
57
|
Gospodarowicz MK, Henson DE, Hutter RVP,
O'Sullivan B, Sobin LH and Wittekind CL: Prognostic Factors in
Cancer. 2nd edition. Wiley-Liss; New York: 2001
|
|
58
|
Passler C, Scheuba C, Prager G, Kaczirek
K, Kaserer K, Zettinig G and Niederle B: Prognostic factors of
papillary and follicular thyroid cancer: Differences in an
iodine-replete endemic goiter region. Endocr Relat Cancer.
11:131–139. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Baldini E, Sorrenti S, Tuccilli C, Prinzi
N, Coccaro C, Catania A, Filippini A, Bononi M, De Antoni E,
D'Armiento M, et al: Emerging molecular markers for the prognosis
of differentiated thyroid cancer patients. Int J Surg. 12(Suppl 1):
S52–S56. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Ulisse S, Baldini E, Sorrenti S, Barollo
S, Gnessi L, Catania A, Pellizzo MR, Nardi F, Mian C, De Antoni E,
et al: High expression of the urokinase plasminogen activator and
its cognate receptor associates with advanced stages and reduced
disease- free interval in papillary thyroid carcinoma. J Clin
Endocrinol Metab. 96:504–508. 2011. View Article : Google Scholar
|
